Dr Reddy's gains over 3% on new drug launch in the US market

The company launched its generic version of fesoterodine fumarate extended-release tablets that can be used for treating overactive bladder in the US market.

Shares of Dr Reddy’s Laboratories were up 3.4 per cent to Rs 4,553.70 on the BSE in Monday’s trade in an otherwise weak market after they launched generic version of fesoterodine fumarate extended-release tablets to treat overactive bladder in the US market.

The company along with its subsidiaries announced the launch of Dr. Reddy’s Fesoterodine Fumarate Extended-Release Tablets, a therapeutic generic equivalent to Toviaz® (fesoterodine fumarate) extended-release tablets in the U.S. market approved by the U.S. Food and Drug Administration (USFDA). The company’s fesoterodine fumarate extended-release tablets are available in 4 mg and 8 mg tablets, each in bottle